Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Champions OncologyCSBR -3.53%62 1-Year Share Buyback Ratio is -1.00 as of Jul. 2026. GuruFocus rates CSBR with a GF Score™ of 62/100 and a GF Value™ of $6.51 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,106 Biotechnology companies, Champions Oncology ranks better than 80.47% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Champions Oncology's current 1-Year Share Buyback Ratio was -1.00%.
CSBR's 1-Year Share Buyback Ratio is ranked better than 80.47% of 1106
companies
in the Biotechnology industry
Industry Median: -14.1
vs CSBR: -1.00
Champions Oncology (NAS:CSBR) 1-Year Share Buyback Ratio Explanation
A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Champions Oncology 1-Year Share Buyback Ratio Related Terms
CSBR vs PLRX, IBIO, XBIT: 1-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, Champions Oncology's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology 1-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's 1-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Champions Oncology's 1-Year Share Buyback Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 1-Year Share Buyback Ratio of -1.00 mean?
Champions Oncology (CSBR) has a 1-Year Share Buyback Ratio of -1.00 as of Jul. 2026. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #216 out of 1106 companies in the Biotechnology industry, placing it in the top 19.5%.
Is Champions Oncology's 1-Year Share Buyback Ratio too high?
Champions Oncology's current 1-Year Share Buyback Ratio is -1.00. Based on the distribution chart, Champions Oncology ranks #216 out of 1106 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Champions Oncology has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's 1-Year Share Buyback Ratio compare to PLRX and IBIO?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #216 out of 1106 companies for 1-Year Share Buyback Ratio. This places Champions Oncology in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Share Buyback Ratio for a Biotechnology company?
A good 1-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 1-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Share Buyback Ratio mean?
A high 1-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. View historical data for Champions Oncology and its competitors. Champions Oncology's current 1-Year Share Buyback Ratio is -1.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.51, compared to a current price of $4.92 — trading 24.4% below its estimated fair value. The current 1-Year Share Buyback Ratio is -1.00. Champions Oncology's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Share Buyback Ratio calculated?
1-Year Share Buyback Ratio is calculated from a company's financial statements. For Champions Oncology (CSBR), the current 1-Year Share Buyback Ratio is -1.00 as of Jul. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $4.92 is trading 24.4% below its estimated GF Value™ of $6.51.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
1-Year Share Buyback Ratio: -1.00
GF Value™: $6.51 vs. price of $4.92 (24.4% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
62GF Score
Get the complete analysis for CSBR
1-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
